X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Physitrack plc

Physitrack examines the business value of physical therapy certifications

Physical therapy certifications can improve career access and service positioning, but the financial return depends on how specialist skills are used and rewarded...
Genflow Biosciences Plc

Genflow Biosciences comes into focus as pet longevity demand grows

Genflow Biosciences moves into sharper focus as pet longevity shifts towards evidence, prevention and healthier ageing...
BIOG

Rhythm Pharmaceuticals gains Japan approval for IMCIVREE in hypothalamic obesity

Rhythm Pharmaceuticals has secured Japanese approval for IMCIVREE in acquired hypothalamic obesity, expanding the commercial opportunity for its lead rare-disease treatment...
EDX

EDX Medical begins second phase of Scottish Prostate Cancer Testing Initiative

EDX Medical has begun the second phase of the Scottish Prostate Cancer Initiative, with 12,500 more men set to receive free PSA testing as part of a programme aiming to..
AstraZeneca

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52...
CTEC

Convatec appoints Jens Viebke as Non-Executive Director

Convatec has appointed Dr Jens Viebke as a Non-Executive Director with immediate effect and added him to the Remuneration Committee...
Physitrack plc

Champion Health uses physiotherapist review to strengthen digital MSK triage

Champion Health's Nexa puts a registered physiotherapist into every MSK treatment decision, aiming to reduce delays, improve treatment suitability and make absence outcomes easier to measure...
NFX

Nuformix Dr Dan Gooding on positive NXP002 study results and next steps

Nuformix says new preclinical results for inhaled NXP002 support its development as a potential treatment for idiopathic pulmonary fibrosis, showing lung concentrations in a therapeutic range, target pathway engagement and..
CIZ

Cizzle Bio expands the clinical pathway for CIZ1B Lung Cancer testing

Cizzle Bio has established a provider ordering and onboarding pathway for its CIZ1B lung cancer blood test in Dallas-Fort Worth and San Antonio, creating a structured route for clinical adoption...
Verici Dx Plc

New BK virus research targets a major kidney transplant treatment gap

Oxford researchers are investigating whether HIF inhibitors could provide a new way to control BK virus in kidney transplant patients...
ONT

Oxford Nanopore appoints David Miller as Chief Development and Product Officer

Oxford Nanopore Technologies has appointed David Miller as Chief Development and Product Officer and confirmed Conor McKechnie as Chief Marketing and Communications Officer. The new executive hires, both joining the..
AZN

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026...
NFX

Nuformix appoints Tim Metcalfe as Non-Executive Chairman

Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons...
PTRK

Physitrack reports 8% revenue growth and profitable Q2 2026

Physitrack reported Q2 2026 revenue of €3.4 million, up 8% year on year, with adjusted EBITDA of €1.2 million and a 34% margin. The company highlighted continued Lifecare growth, the..
EDX Medical Group plc

EDX Medical raises £2.7m to expand employee health screening service

EDX Medical has raised approximately £2.7m through a share subscription to support the expansion of its employee health screening service, as discussions progress with several major UK employers...
GSK

GSK gains priority FDA review for Jemperli in rectal cancer

GSK says the US FDA has accepted Jemperli for priority review in previously untreated stage II and III locally advanced rectal cancer...
Verici Dx Plc

Verici Dx adds new proteomics revenue opportunity

Verici Dx has added a new proteomics service offering that could broaden revenue while making greater use of its existing US laboratory...
Nuformix plc

Nuformix adds new preclinical support for NXP002

Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions...
SPI

Spire Healthcare updates interim results release date

Spire Healthcare has delayed the expected release of its interim results for the six months ended 30 June 2026 to 30 September 2026...
Nuformix Interview

Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Physitrack plc

Physitrack examines the business value of physical therapy certifications

Physical therapy certifications can improve career access and service positioning, but the financial return depends on how specialist skills are used and rewarded...
Genflow Biosciences Plc

Genflow Biosciences comes into focus as pet longevity demand grows

Genflow Biosciences moves into sharper focus as pet longevity shifts towards evidence, prevention and healthier ageing...
BIOG

Rhythm Pharmaceuticals gains Japan approval for IMCIVREE in hypothalamic obesity

Rhythm Pharmaceuticals has secured Japanese approval for IMCIVREE in acquired hypothalamic obesity, expanding the commercial opportunity for its lead rare-disease treatment...
EDX

EDX Medical begins second phase of Scottish Prostate Cancer Testing Initiative

EDX Medical has begun the second phase of the Scottish Prostate Cancer Initiative, with 12,500 more men set to receive free PSA testing as part of a programme aiming to test 25,000 men across Scotland...
AstraZeneca

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52...
CTEC

Convatec appoints Jens Viebke as Non-Executive Director

Convatec has appointed Dr Jens Viebke as a Non-Executive Director with immediate effect and added him to the Remuneration Committee...
Physitrack plc

Champion Health uses physiotherapist review to strengthen digital MSK triage

Champion Health's Nexa puts a registered physiotherapist into every MSK treatment decision, aiming to reduce delays, improve treatment suitability and make absence outcomes easier to measure...
NFX

Nuformix Dr Dan Gooding on positive NXP002 study results and next steps

Nuformix says new preclinical results for inhaled NXP002 support its development as a potential treatment for idiopathic pulmonary fibrosis, showing lung concentrations in a therapeutic range, target pathway engagement and evidence of a viable safety window. The company is now advancing target identification work, planning toxicology studies and continuing partnering discussions ahead of the European Respiratory Society Congress...
CIZ

Cizzle Bio expands the clinical pathway for CIZ1B Lung Cancer testing

Cizzle Bio has established a provider ordering and onboarding pathway for its CIZ1B lung cancer blood test in Dallas-Fort Worth and San Antonio, creating a structured route for clinical adoption...
Verici Dx Plc

New BK virus research targets a major kidney transplant treatment gap

Oxford researchers are investigating whether HIF inhibitors could provide a new way to control BK virus in kidney transplant patients...
ONT

Oxford Nanopore appoints David Miller as Chief Development and Product Officer

Oxford Nanopore Technologies has appointed David Miller as Chief Development and Product Officer and confirmed Conor McKechnie as Chief Marketing and Communications Officer. The new executive hires, both joining the leadership team this autumn, are intended to align product development, marketing and commercial execution as the company scales its differentiated technology platform...
AZN

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026...
NFX

Nuformix appoints Tim Metcalfe as Non-Executive Chairman

Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons...
PTRK

Physitrack reports 8% revenue growth and profitable Q2 2026

Physitrack reported Q2 2026 revenue of €3.4 million, up 8% year on year, with adjusted EBITDA of €1.2 million and a 34% margin. The company highlighted continued Lifecare growth, the US launch of its Remote Therapeutic Monitoring platform and further investment in North American expansion...
EDX Medical Group plc

EDX Medical raises £2.7m to expand employee health screening service

EDX Medical has raised approximately £2.7m through a share subscription to support the expansion of its employee health screening service, as discussions progress with several major UK employers...
GSK

GSK gains priority FDA review for Jemperli in rectal cancer

GSK says the US FDA has accepted Jemperli for priority review in previously untreated stage II and III locally advanced rectal cancer...
Verici Dx Plc

Verici Dx adds new proteomics revenue opportunity

Verici Dx has added a new proteomics service offering that could broaden revenue while making greater use of its existing US laboratory...
Nuformix plc

Nuformix adds new preclinical support for NXP002

Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions...
SPI

Spire Healthcare updates interim results release date

Spire Healthcare has delayed the expected release of its interim results for the six months ended 30 June 2026 to 30 September 2026...
Nuformix Interview

Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple